Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Published Online: 2020-12-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Bohuslav Melichar•Brian I Rini•Delphine Borchiellini•Denis Soulières•Dmitry Nosov•Elizabeth R Plimack•Frédéric Pouliot•Ihor Vynnychenko•Jens Bedke•L Rhoda Molife•Lina Yin•Mei Chen•Michael B Atkins•Raymond S McDermott•Rustem Gafanov•Satoshi Tamada•Sergio J Azevedo•Thomas Powles•Tom Waddell•Viktor Stus
